Skip Navigation

Repertoire Immune Medicines to Present at the 32nd Annual Piper Sandler Virtual Healthcare Conference

CAMBRIDGE, Mass. – November 24, 2020 – Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmune and infectious disease, will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference on Monday, November 30,2020.

About Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. The company is founded on the belief that the repertoire of T cell receptor(TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science.Repertoire scientists created and developed the DECODE and DEPLOY suite of technologies, which allow in-depth characterization of TCR-antigen pairings, and the ability to rationally design and clinically develop targeted immune medicines.

From our sites in Cambridge, Mass., and Zurich, Switzerland, our team of more than 120 is creating a new category of immune medicines enabled from our DECODE discovery platform. Our first product in the clinic is a novel multi-clonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens and armed with our proprietary cytokine payload. We are in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, we are using our proprietary platform to discover novel epitopes and TCRs, starting with known and unique epitopes from Type 1 diabetes. We also are using our DECODE platform to discover infectious disease antigens and responding T cell clones, particularly in SARS-COV2.

To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.

Investor Contact:

Kendall Investor Relations
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

Media Contact:

Scient Public Relations
Lindsay G. Deefholts
ldeefholts@scientpr.com